Letters to the Editor

Patten SB Williams JVA Haynes L McCruden J Arboleda-Florez J. The incidence of delirium in psychiatric inpatient units. Can J Psychiatry 1997;42:858–63.

Statistics Canada. Mental Health Statistics. Mental Health Statistics Publication #83–245. Ottawa: Minister of Supply and Services, Canada; Annual.

Lalonde A. Canadian Institute for Health Information: Founding members. Canadian Journal of Medical Technology 1994;56:79.

Garcia-Campayo J Sanz-Carillo C Lobo A. Orgasmic sexual experiences as a side effect of fluoxetine: A case report. Acta Psychiatr Scand 1995;91:69–70.

McLean JD Forsythe RG Kapkin IA . Unusual side effects of clomipramine associated with yawning. Can J Psychiatry 1983;28:569–70.

Gardner EA Johnston JA . Bupropion: An antidepressant without sexual pathophysiological action. J Clin Psychopharmacol 1985;5:24–9.

Labbate LA Pollack MH . Treatment of fluoxetine induced sexual dysfunction with bupropion. Ann Clin Psychiatry 1994;6:13–5.

Rowland DL Myers L Culver A Davidson JM . Bupropion and sexual function: A placebo controlled prospective study on diabetic men with erectile dysfunction. J Clin Psychopharmacol 1997;17:350–7.

Baker RW Chengappa KNR Baird JW Steingard S Christ MAG Schooler NR . Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992;53:439–42.

Remington G Adams M. Risperidone and obsessive compulsive symptoms [letter]. J Clin Psychopharmacol 1994;14:358–9.

Bymaster FP Calligaro DO Falcone JF Marsh RD Moore NA Tye NC , and others. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996;14:87–96.

Price LH Goddard AW Barr LC Goodman WK . Pharmacological challenges in anxiety disorders. In: Bloom FE Kupfer DJ , editors. Psychopharmacology: The fourth generation of progress. New York: Raven Press; 1995. p 1311–23.

Preskorn SH . Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32:1–21.

LoCorto MJ . The serotonin syndrome. Emerg Med Clin North Am 1997; 15:665–75.

Bruno A Cumer BS . Effects of 1-dopa on pharmacological parkinsonism. Acta Psychiatrica Scandinavia 1966;42:264–71.

Shoulson I. Carbidopa/levodopa therapy of coexistent drug-induce parkinsonism and tardive dyskinesia. Adv Neurol 1983;37:253–8.

Fleming P Makar H Hunter KR . Levodopa in drug-induced extrapyramidal disorder [letter]. Lancet 1970;2:1186.

Yaryura-Tobias JA Wolpert A Sana L Merlis S. Action of L-dopa in drug induce extrapyramidalism. Diseases of the Nervous System 1970;31:60–3.

Chouinard G Annable L Mercier P Turnier L. Long-term effects of 1-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol Bull 1987;23:221–6.

Chouinard G Ross-Chouinard A Gauthier S Annable L Mercier P. An extrapyramidal rating scale for idiopathic and neuroleptic-induce parkinsonism and dyskinesia (abstract F-13). 14th Collegium Intemionale Neuro-Psychopharma-cologicum (CINP) Congress Abstracts, 1984.

Benazzi F. Prevalence of bipolar II disorder in outpatient depression: A 203-case study in private practice. J Affect Disord 1997;43:163–6.

Benazzi F. Antidpressant-associated hypomania in outpatient depression: A 203-case study in private practice. J Affect Disord 1997;46:73–7.

Andreasen NC Flaum M Arndt S. The comprehensive assessment of symptoms and history (CASH). Arch Gen Psychiatry 1992;49:615–23.

Montgomery SA Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382–9.

American Psychiatric Association. Diagnostic and statistical manual of mental disorder. 4th ed. Washington (DC): American Psychiatric Press; 1994.